Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis

Vanessa J. Craig1, Sergio B. Cogliatti2, Hubert Rehrauer3, Thomas Wündisch4 and Anne Müller1*

1Institute of Molecular Cancer Research and 3Functional Genomics Center Zürich, University of Zürich, 8057 Zürich, Switzerland
2Institute of Pathology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland
4Department of Hematology, Oncology and Immunology, Philipps-University, 35033 Marburg, Germany

*For correspondence: Anne Müller, Institute of Molecular Cancer Research, Univ. of Zürich, Winterthurerstr. 190, 8057 Zürich, Switzerland; mueller@imcr.uzh.ch; phone: ++41 44 635 3474; fax: ++41 44 635 3484

Running head: Epigenetic silencing of miR-203 drives MALT lymphomagenesis

Word count: Abstract, 250; Text: 4371 excluding references.
Abstract

Gastric B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) develops in the chronically inflamed mucosa of patients infected with the bacterial pathogen *Helicobacter pylori*. Here we use patient material, primary gastric lymphoma cell cultures and a preclinical model of the disease to examine the role of microRNA-mediated post-transcriptional regulation –focusing in particular on miR-203 and its target ABL1- in gastric MALT lymphomagenesis. Microarray-based microRNA expression profiling revealed a strong down-regulation of the putative tumor suppressor microRNA miR-203 in human MALT lymphoma samples, which resulted from extensive promoter hypermethylation of the miR-203 locus and coincided with the dysregulation of the miR-203 target ABL1 in lymphoma biopsies compared to matched adjacent normal material from the same patients. Treatment of lymphoma B-cells with demethylating agents led to increased miR-203 expression and the concomitant down-regulation of ABL1, confirming the epigenetic regulation of this microRNA. Ectopic re-expression of miR-203 by transfection of a human lymphoma cell line or lentiviral transduction of explanted primary MALT lymphoma cells was sufficient to prevent tumor cell proliferation *in vitro*. Similarly, the treatment of primary MALT lymphoma cells with the ABL inhibitors imatinib and dasatinib prevented tumor cell growth. Finally, we show that the treatment of tumor-bearing mice with imatinib induces MALT lymphoma regression in a preclinical model of the disease, implicating ABL1 in MALT lymphoma progression. In summary, our results show that the transformation from gastritis to MALT lymphoma is epigenetically regulated by miR-203 promoter methylation and identify ABL1 as a novel target for the treatment of this malignancy.
Introduction

Mucosa-associated lymphoid tissue (MALT) lymphomas account for 8% of all non-Hodgkin’s lymphomas (1). The development of gastric MALT lymphoma is tightly linked to chronic infection with the human bacterial pathogen Helicobacter pylori (2); consequently, antibiotic eradication therapy is now used as the first line treatment of this malignancy (3-6). MALT lymphomagenesis is initiated by H. pylori-associated chronic inflammation and the subsequent accumulation of gastric organized lymphoid tissue, from which individual neoplastic clones may grow out and invade the adjacent epithelium (2). We have shown recently that MALT lymphoma tumor immunoglobulins (Ig) are clonal, somatically hypermutated and polyreactive, i.e. they bind to a variety of unrelated self- and foreign antigens (7). The same panel of antigens that are recognized by MALT lymphoma surface Ig induce proliferation of explanted tumor cells, supporting the notion that early low grade gastric MALT lymphoma is an antigen-dependent malignancy (8). Low grade gastric MALT lymphomas are infiltrated by large numbers of T-cells, which are polarized to produce Th2 cytokines such as interleukin-4 (9, 10). The depletion of T-cells prevents the proliferation of tumor cells ex vivo and induces tumor regression in a mouse model of gastric MALT lymphoma (8), implying a synergistic role for T-cell-derived growth signals and B-cell receptor-mediated antigen recognition during early MALT lymphoma development.

Low grade human MALT lymphoma can be modeled by chronic experimental infection of BALB/c mice with Helicobacter species (10-13). In mice, disease progression is reflected by specific gene expression signatures of histologically defined disease stages (13); similar signatures are found in human biopsies of gastritis vs. low grade lymphoma.
material (14). The number of genes that are differentially expressed between reactive and neoplastic lesions is remarkably low in both species (13, 14), suggesting that the two tissues are biologically similar. In conjunction with the reversibility of the early tumors upon *Helicobacter* eradication therapy in humans (3, 4, 15) and mice (10, 12), the biological similarity implies that epigenetic and other regulatory processes rather than genetic events drive MALT lymphoma progression in the early stages.

MicroRNAs (miRNAs) are well-conserved, 18-25 nucleotide long non-coding RNAs with pivotal roles in post-transcriptional gene regulation (16). miRNA expression patterns correlate with particular cancer types (17) and are predictive of clinical outcome (18, 19). Over 50% of miRNA genes are located in cancer-associated genomic regions (20). Many miRNAs are known to function as tumor suppressors, regulating the expression of oncoproteins such as RAS (21) and c-MYC (22). Here, we demonstrate that miR-203 is specifically down-regulated in gastric MALT lymphoma due to promoter hypermethylation. The ectopic re-expression of miR-203 in primary MALT lymphoma cells silences the expression of the miR-203 target ABL1 and blocks tumor cell proliferation in vitro. Inhibition of ABL1’s tyrosine kinase activity by imatinib blocks MALT lymphoma cell proliferation ex vivo and prevents tumor formation in mice, suggesting for the first time an important oncogenic role for ABL1 in the pathogenesis of a malignancy not harboring the t(9;22) chromosomal translocation fusing the *BCR* and *ABL* loci.
Materials and Methods

Patient material and cell lines

Human material was obtained from eight patients with *H. pylori*-positive, t(11;18)(q21;q21)-negative gastric low grade MALT lymphoma that were part of a previously published study conducted at Philipps-University Hospital Marburg, Germany (14). The whole genome-based miRNA expression analysis was performed using fresh frozen cases of *H. pylori*-positive gastric low grade MALT lymphoma and tonsil material drawn from the surgical pathology files of the Institute of Pathology at the Cantonal Hospital St. Gallen, Switzerland. miR-203 down-regulation and promoter methylation was examined using archived formalin-fixed, paraffin embedded tonsil material and biopsies of *H. pylori*-positive chronic active gastritis, *H. pylori*-positive gastric low grade MALT lymphoma and gastric DLBCL from the Institute of Pathology, Cantonal Hospital St. Gallen. All data were blinded to guarantee patients' protection and were generated in agreement with the guidelines for use of human material in research issued by the participating Institutions’ Ethics Committees. The Burkitt’s lymphoma cell line BL2 was kindly provided by Prof. Dr. Jean-Claude Weill (Hôpital Necker, Paris, France); BL2 cells are EBV-negative and were generated from the bone marrow of a pediatric non-endemic Burkitt lymphoma patient (23). Cell line authentication was performed at the onset of the experiments described here and included flow cytometric verification of surface marker expression (CD19, CD20, IgM, HLA-DR) and verification of the IGL-MYC translocation by genomic PCR.
Animal experimentation, cell culture, nucleoporation and FACS sorting

Female BALB/c mice were infected intragastrically at six weeks of age with 5x10^7 *H. felis* (CS1, ATCC 49179). All procedures were approved by the Zurich cantonal veterinary office. Mice received 75mg/kg per day imatinib in their drinking water for the final 3 months of an 18 month infection experiment. After 18 months, macroscopically visible gastric tumors were collected, single cell suspensions were generated and cultured for 3 days in RPMI/10 % FCS with 10 µg/ml *Helicobacter* lysate and 0.01-30 µM imatinib or dasatinib (generously provided by Novartis, Basel, Switzerland and C. Nevada, Institute of Organic Chemistry, University of Zurich, respectively). Tumor cell proliferation was quantified by [3H]-thymidine incorporation. For DNA demethylation, BL2 cells were treated with 5 µM 5’-azacytidine and/or 3 mM 4-phenylbutyric acid (both from Sigma-Aldrich). For the purpose of miR-203 re-expression, 1x10^6 BL2 cells were nucleoporated using an Amaxa Nucleoporator (Gaithersburg, MD) with miR-203 precursor or negative control oligonucleotides (both from Ambion, Austin, TX) and harvested 48 hours later for ABL1 expression analysis by qRT-PCR or Western Blot. For sorting of pure B-cell populations, splenic B-cells were immunomagnetically purified (B-cell isolation kit, R&D Systems), stained with antibodies against CD21 (clone 7G6; BD Pharmingen) and CD23 (clone B3B4; Biolegend) and sorted to >95% purity on a FACS Aria (Becton Dickinson) prior to miR-203 qPCR analysis.

Lentivirus production and infection

The pre-miR-203 lentiviral expression construct used to re-express mature mir-203 in murine primary lymphoma cells was purchased from Systems Biosciences (Mountain...
Third-generation lentiviral vector packaging constructs were generously provided by Stefano Ferrari from the Institute of Molecular Cancer Research, Univ. of Zurich, and consisted of the three plasmids pMDLg/pRRE, pHCMV-G and pRSVrev. The pre-miR-203 expression vector (2.5 μg) was transfected along with the lentivirus packaging plasmids (2.5 μg of each plasmid) into HEK293T cells and the supernatant was collected 48 and 72 hours after transfection. Primary lymphoma cells were incubated with the viral particles. Empty lentivirus was used as a control. *H. felis* stimulated primary MALT lymphoma cells were transduced in the presence of polybrene (8 μg/ml) by spinoculation in a centrifuge at 700 x g for 90 minutes at room temperature in a 96-well plate. 72 hours following infection, tumor cell proliferation was quantified by [3H]-thymidine incorporation assay. Expression of mature miR-203 was validated by real-time qPCR.

**Microarray-based miRNA expression profiling**

Total RNA (including miRNA) was extracted from fresh frozen and FFPE biopsy samples (three 20 μm slices) using the RecoverAll total RNA Isolation kit (Ambion, Streetsville, Canada). RNA integrity was evaluated using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). miRNA microarray experiments were performed using the Agilent Human miRNA Microarray Kit version 10.0. For each sample, 100 ng total RNA were hybridized with the miRNA array and further processed according to Agilent's miRNA Microarray System protocol. The arrays were scanned with an Agilent Technology G2565B scanner (Agilent Technologies, Palo Alto, CA). The scanned images were gridded and analysed using Agilent Feature Extraction Software.
version 9.5. Normalization and statistical analysis was performed with R/Bioconductor. Specifically, we used the quantile normalization implemented in the package PreprocessCore and ran the statistical test using the package genefilter. The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) (24) and are publicly accessible through GEO Series accession number GSE23877.

**miR-203 and ABL1 expression analysis and bisulfite sequencing**

Expression of mature miR-203 was analyzed using the miRCURY locked nucleic acid (LNA) microRNA PCR system following the manufactures’ protocol (Exiqon). Briefly, 10 ng of total RNA was subjected to cDNA synthesis using miR-203 or U6 snRNA-specific primers. The cDNA template was diluted 1:10 and real time PCR reactions were performed following the manufactures’ recommendations (LightCycler; Roche, Basel, CH). Calculations of miRNA expression levels were performed using the comparative $\Delta\Delta C_t$ method and normalized against U6 snRNA levels. ABL1-specific real time RT-PCR (LightCycler; Roche, Basel, CH) was performed with the LightCycler 480 SYBR Green I master kit (Roche). GAPDH transcript levels were determined for normalization. Human and murine ABL1 primers were published previously (25, 26). Protein extracts were made using either RIPA cell lysis buffer (50 mM Tris-HCl [pH7.5], 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1 mM PMSF) or 2x Laemmli sample buffer (4% SDS, 20% glycerol, 120 mM Tris [pH 6.8]). Proteins were separated by SDS/polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. Membranes were probed with antibodies against ABL1 (BD Biosciences,
CA, USA) and α-tubulin (Sigma-Aldrich, St. Louis, MO). Specific oligonucleotides for bisulfite sequencing of the miR-203 CpG island were described previously (27). Genomic DNA was isolated from FFPE tissue or fresh material using the RecoverAll total RNA Isolation kit (Ambion, Streetsville, Canada) or the Quiagen DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA), respectively. 2 µg gDNA was converted with sodium bisulfite as previously reported (28). Following amplification of the bisulfite-converted DNA, the methylation status was assessed by sequencing the miR-203 bisulfite converted promotor region.
Results

The expression of miR-203 and of its target ABL1 is dysregulated in MALT lymphoma

In order to identify miRNAs that are differentially expressed in human *Helicobacter*-associated MALT lymphoma compared to normal lymphoid tissue, we generated microarray-based expression profiles for five low-grade MALT lymphoma and four tonsil samples that included all 795 currently annotated human mature miRNAs. Tonsil material was used as a reference because of its comparable cellular composition (B-cells make up ~60-70% of cells in tonsil tissue and in MALT lymphoma) (8). Of the 157 miRNAs exhibiting high variation across the nine samples (Supplemental Table 1), six were strongly down-regulated in all cases of lymphoma, but in none of the tonsil samples (annotated in Figure 1A). Of these six miRNAs, three were predicted by miRNA target prediction algorithms (TargetScan, miRDB, miRWalk) to post-transcriptionally regulate the non-receptor tyrosine kinase ABL1 (c-Abl) and/or the closely related ABL2 kinase (also called ARG for “Abl-related gene”). miR-203 (which was down-regulated by on average 10 fold in MALT lymphoma compared to tonsil tissue) binds to position 1074 in the ABL1 3’UTR (27), and is predicted to also target three sites in the ABL2 3’UTR (1291, 4963 and 7951). miR141 and miR205 are predicted to target both ABL kinases and ABL2 only, respectively. We focused our attention on miR-203 because it has previously been implicated in tumor suppression (27) and has also been identified in a recent screen comparing miRNA expression in the normal, *H. pylori*-negative gastric mucosa and *H. pylori*-positive gastritis (29). Its dysregulation could be confirmed by quantitative (q)PCR in the samples used for expression profiling as well as in an independent set of archived cases of *Helicobacter*-associated gastritis and gastric MALT.
lymphoma (Figure 1B,C). As miR-203 is known to regulate ABL1 (27), we assessed ABL1 expression in eight cases of gastric MALT lymphoma for which matched gastritis material was available. qPCR analysis revealed that seven of the eight lymphoma samples exhibited higher ABL1 expression than the corresponding gastritis (Figure 1D). Similar patterns of inverse miR-203 and ABL1 expression were detected in four matching pairs of gastric lymphoma and corresponding gastritis harvested from BALB/c mice that had been infected with *Helicobacter felis* for 18 months to induce gastric MALT lymphoma (Figure 1E, F). To verify that the loss of expression of miR-203 was indeed a pathological phenomenon, we FACS-sorted populations of murine splenic B-cells to >95% purity based on their CD21/CD23 expression and examined their miR-203 expression relative to murine gastritis and MALT lymphoma tissue (Figure 1G). Whereas immature B-cells (CD21^lo^, CD23^−^) and T2 marginal zone precursor cells (CD21^hi^, CD23^−^) exhibited only low level expression of miR-203, marginal zone B-cells (CD21^hi^, CD23^−^; the normal cell counterpart of MALT lymphoma cells) and follicular B-cells (CD21^int^, CD23^+^) expressed extremely high levels of miR-203 in relation to gastritis and tumor tissue (Figure 1G). The results suggest that expression of miR-203 is induced in the course of B-cell maturation, and is secondarily lost as marginal zone B-cells undergo neoplastic transformation during MALT lymphomagenesis. In summary, both miR-203 and its target ABL1 are differentially regulated in human gastric lymphoma as well as in a mouse model of the disease, implicating ABL1 as a possible target of miR-203 in MALT lymphomagenesis.
The miR-203 promoter is specifically hypermethylated in MALT lymphoma

The promoter region of the miR-203 genomic locus contains a CpG island flanking the transcriptional start site (Figure 2A), which has been shown to be hypermethylated in certain hematological malignancies and hepatocellular carcinoma (27, 30). We determined the methylation status of the miR-203 promoter in several cases each of normal human tonsil, gastritis, low grade gastric MALT lymphoma and gastric DLBCL by sodium bisulfite genomic sequencing. The miR-203 promoter region was heavily methylated in the majority of independent clones analyzed for all MALT lymphoma and gastric DLBCL samples, but was largely unmethylated in the tonsil and gastritis tissues (Figure 2B). In conclusion, the miR-203 promoter appears to be specifically hypermethylated in MALT lymphoma, which may lead to silencing of the genomic locus and may contribute to MALT lymphomagenesis.

The expression of miR-203 is epigenetically regulated and controls ABL1 levels and lymphoma cell proliferation in vitro

To determine whether promoter methylation indeed affects miR-203 transcription, and as a consequence, ABL1 expression, we took advantage of a non-Hodgkin’s lymphoma cell line exhibiting a degree of miR-203 promoter methylation that is comparable to that found in human MALT lymphoma (BL2; Figure 3A). The treatment of BL2 cells with the DNA-demethylating agent 5'-azacytidine (Aza), either alone or in combination with the histone deacetylase inhibitor 4-phenylbutyric acid (PBA), resulted in decreased miR-203 promoter methylation and a concomitant rise in miR-203 expression (Figure 3A,B); the expression of ABL1 was inversely correlated with miR-203 at both the mRNA and
protein levels (Figure 3C,D). The combined treatment with both compounds resulted in a more efficient drop in promoter methylation and a greater increase in miR-203 expression, but did not further reduce ABL1 expression (Figure 3A-D). To confirm directly that miR-203 targets ABL1, pre-miR-203 precursor molecules were introduced into BL2 cells by electroporation. The ectopic expression of pre-miR-203 led to a significant down-regulation of ABL1 expression at both the mRNA and the protein levels as compared to a scrambled negative control pre-miR (Figure 3E,F) and blocked the proliferation of BL2 cells as determined by [3H]-thymidine incorporation (Figure 3G). The combined results suggest that miR-203 is epigenetically regulated and acts as a tumor suppressor miRNA through its effects on ABL1 expression.

The proliferation of MALT lymphoma cells is blocked by imatinib in vitro and in vivo

To assess the effects of miR-203 delivery on primary murine MALT lymphoma cells, we generated lentiviral particles carrying a miR-203-encoding expression vector and transduced primary murine gastric MALT lymphoma cells isolated from BALB/c mice that had been infected with *H. felis* for 18 months. The lentiviral delivery of miR-203 to explanted murine MALT lymphoma cells resulted in increased miR-203 levels, decreased ABL1 expression and a concomitant block in the *Helicobacter* antigen-dependent proliferation of the cells (Figure 4A-C). These observations raised the possibility that ABL inhibitors such as imatinib (Gleevec) might prevent the proliferation of primary MALT lymphoma cells in vitro and in vivo. Indeed, addition of imatinib to the primary cell cultures efficiently blocked their proliferation in a dose-dependent manner (Figure 4D); similar results were obtained with the ABL inhibitor dasatinib (Figure 4D).
cells that had spread to the spleen were equally sensitive to ABL inhibition as cells derived from the primary gastric tumor (Figure 4E). To assess a possible therapeutic effect of imatinib in a preclinical model of *Helicobacter*-induced MALT lymphoma, BALB/c mice were infected for 15 months with *H. felis* to allow for lymphoma development. A group of mice received imatinib via the drinking water for the following three months while all other mice remained untreated. Whereas between 2 to 15 tumors had formed in the majority of control mice, all imatinib-treated mice were tumor free as assessed macroscopically and histopathologically at the 18 month post infection endpoint of the study (Figure 4F,G). Imatinib had no effect on *H. felis* colonization densities (Figure 4H), ruling out a direct effect of the treatment on the underlying infection. The combined results suggest that miR-203 re-expression in murine primary MALT lymphoma cells prevents their proliferation and that this effect is mediated by the tyrosine kinase activity of the miR-203 target ABL1 *in vitro* and *in vivo*. 
Discussion

Our array-based miRNA transcriptome analysis identified miR-203 as one of the most strongly down-regulated miRNAs in gastric lymphoma compared to normal lymphoid tissue; its dysregulation could be attributed to extensive promoter hypermethylation. Our results further suggest that the loss of miR-203 expression and the resulting dysregulation of its target ABL1 contribute directly to gastric lymphomagenesis and thus identify ABL1 as a new target in the treatment of this malignancy. Several previous reports have indicated a tumor suppressive role for miR-203. It is encoded on a fragile 7Mb region of murine chromosome 12 that encodes ~12% of all genomic miRNAs and that is frequently deleted in hematopoietic malignancies (27). Its expression is downregulated in cancers of the liver (31), central nervous system (32) and in some types of leukemia (27). Experimental inhibition of miR-203 enhances the growth of lung carcinoma cells (33); conversely, the experimental restoration of miR-203 expression significantly reduces the proliferation of hepatocellular carcinoma (30), of certain leukemias such as chronic myelogenous leukemia (CML) (27) and of head and neck squamous cell carcinoma (34). MALT lymphomas are negative for the Philadelphia chromosome (Ph−), i.e. they do not harbor the t(9;22) reciprocal translocation fusing the BCR and ABL1 gene loci that is a hallmark of CML and of a subset of acute lymphoblastic leukemias (ALL) (35). However, we found that wild type ABL1 is significantly more strongly expressed in human MALT lymphoma biopsies than in corresponding gastritis material from the same patient. The treatment of BL2 cells (which are also Ph− and harbor a comparably methylated miR-203 promoter region) with demethylating agents and the consequent re-expression of miR-203 repressed cellular ABL1 levels and reduced BL2 proliferation,
showing that miR-203 can function as a tumor suppressor independently of the t(9;22) translocation.

ABL1 is predominantly expressed in the hematopoietic system, in particular in lymphocytes; the targeted deletion or mutation of ABL1 in mice results in splenic and thymic atrophy and lymphopenia as well as increased susceptibility to infections (36). In B-cells, ABL1 functions in B-cell receptor signaling, probably by directly interacting with, and phosphorylating, the BCR co-receptor CD19 (37). ABL1 overexpression has been associated with Ph+ hematopoietic malignancies such as chronic lymphocytic leukemia (CLL) (38). In CLL, ABL1 overexpression has been linked to constitutively active BCR signaling and NF-KB activation (38), i.e. to a signaling pathway that is known to contribute to MALT lymphomagenesis (2).

We have shown recently that BCR signaling synergizes with T-cell-derived growth signals to drive MALT lymphoma cell proliferation (8). Inhibition of ABL1 expression by miR-203 replacement or inhibition of its tyrosine kinase activity would therefore be predicted to block the *Helicobacter*-induced proliferation of primary MALT lymphoma cells. Indeed, the lentiviral delivery of miR-203 or treatment of explanted murine MALT lymphoma cells with the tyrosine kinase inhibitor imatinib efficiently prevented their proliferation. The treatment of *Helicobacter*-infected mice prevented or even reversed MALT lymphomagenesis *in vivo*, suggesting that ABL inhibition might be a valid strategy for the treatment of patients that are refractory to eradication therapy. In addition to its beneficial effects in patients with CML (39), imatinib has recently shown promise in adult patients with Ph+ B-cell ALL (35) and has been proposed for the treatment of Ph- CLL patients overexpressing ABL1 (38).
In summary, we show here that the progression from *Helicobacter*-associated gastritis to low grade MALT lymphoma is epigenetically regulated by methylation of the miR-203 promoter region. Transcriptional repression of miR-203 results in dysregulation of ABL1, which in turn drives MALT lymphoma proliferation. Our results identify ABL1 as a promising new target for the treatment of low grade MALT lymphoma, in particular of the ~20% of patients who are refractory to eradication therapy as a first line treatment of the disease.
Acknowledgments

This study was funded by the Swiss Cancer League (OCS-02099-08-2007) and the University of Zurich’s Research Priority Program in Systems Biology. S.B.C. was supported by the Swiss Group for Clinical Cancer Research (SAKK). The authors would like to thank Christoph Renner, David Nadal and Joe Jiricny for helpful discussions.
References

Figure legends

Fig 1. miR-203 and its target ABL1 are dysregulated in MALT lymphoma. (A) Heatmap representation of 157 miRNAs with a standard deviation of log2 expression >0.05 across the four tonsil and five MALT lymphoma samples analyzed on Agilent miRNA microarrays; six strongly down-regulated miRNAs are annotated. (B) Validation of miR-203 expression of the samples shown in A as assessed by locked nucleic acid (LNA) qRT-PCR. miR-203 levels were normalized to U6 snRNA expression. (C) Expression levels of miR-203 in formalin fixed, paraffin-embedded tissue samples of three patients with gastritis and six additional patients with MALT lymphoma as determined by LNA qRT-PCR. (D) ABL1 expression in MALT lymphoma and corresponding gastritis material derived from eight patients. ABL1 transcript levels were quantified by qRT-PCR and normalized to GAPDH expression. (E,F) miR-203 and ABL1 expression in four pairs of murine MALT lymphomas and corresponding gastritis harvested from 18 month infected BALB/c mice. (G) miR-203 expression of FACSp- sorted murine splenic immature B-cells (CD21lo, CD23-), T2 marginal zone precursor cells (TMZ; CD21hi, CD23+), marginal zone B-cells (MZB; CD21hi, CD23+) and follicular B-cells (FO; CD21int, CD23+) in relation to three of the four pairs of murine gastritis/tumor tissue shown in E. * not detectable.

Fig 2. The miR-203 promoter is specifically hypermethylated in gastric lymphoma. (A) Schematic representation of the miR-203 gene embedded in a CpG island showing the 393 bp region analyzed for methylation status. The position of the mature miR-203 sequence is indicated by a triangle. The transcription start site is represented by a bent
arrow. (B) Bisulfite sequencing of the miR-203 upstream region in three human tonsil, three gastritis, four low grade MALT lymphoma and three gastric DLBCL samples. Three representative sequences of three to eight sequenced clones are represented for each sample. Black and white circles represent methylated and unmethylated CpG, respectively. All 61 sequenced CpGs are indicated.

**Fig 3. The expression of miR-203 is regulated epigenetically and controls ABL1 expression and lymphoma cell proliferation.** (A) miR-203 promoter methylation in BL2 cells as determined by bisulfite sequencing. Cells were either treated with 5 µM 5'-azacytidine, alone or in combination with 3 mM 4-phenylbutyric acid, or left untreated. Three representative sequences of three to eight sequenced clones are represented for each treatment condition and the percentage of methylated CpG dinucleotides is shown. Black and white circles represent methylated and unmethylated CpG. (B, C) qPCR analysis of miR-203 and ABL1 expression in BL2 cells with and without drug treatment. (D) ABL1 protein levels of the experiment outlined in A-C as assessed by Western blot analysis with α-tubulin serving as a loading control. (E) Normalized ABL1 expression of BL2 cells transfected with either miR-203 precursor molecules (pre-miR-203) or negative control precursor molecules (N/C) at 50 nM or 100 nM final concentration. (F) ABL1 protein levels of the experiment described in E as assessed by Western blot analysis with α-tubulin serving as loading control. (G) The proliferation of cells transfected as described in E as determined by [3H]-thymidine incorporation. The data shown in A-G are representative of two (A-D) and three (E-G) independent experiments.
Fig 4. miR-203 replacement and pharmacological ABL inhibition block MALT lymphoma growth in vitro and in vivo. (A-C) Primary murine MALT lymphoma cells were transduced with lentiviruses carrying a pre-miR-203-expressing or empty vector. miR-203 and ABL1 expression were assessed by qRT-PCR (A, B); the proliferation of transduced cells was determined by $[^3]$H-thymidine incorporation with or without stimulation with *H. felis* sonicate (C). (D, E) $[^3]$H-thymidine incorporation of gastric (D) and splenic (E) primary murine MALT lymphoma cells stimulated with *H. felis* sonicate and treated with increasing concentrations of imatinib or dasatinib as indicated. Unstimulated cells are included for comparison. Vertical bars indicate standard deviations. The data shown are representative of two (A-C) and three (D, E) independent experiments. (F) Gastric MALT lymphoma formation in female BALB/c mice infected for 18 months with *H. felis*. One group received imatinib through the drinking water for months 16-18 of the experiment. Macroscopically visible tumors >1mm in diameter are plotted. (G) Representative micrographs of H&E-stained sections of the mice shown in F. Scale bar indicates 50 µm. (H) *H. felis* colonization as determined by flaB-specific qPCR of the mice shown in F.
Figure 2

A

miR-203 (14q32.23) → miR-203

CpG island

← BS-PCR region (393bp) →

B

<table>
<thead>
<tr>
<th>tonsil</th>
</tr>
</thead>
<tbody>
<tr>
<td>gastritis</td>
</tr>
<tr>
<td>low grade gastric MALT lymphoma</td>
</tr>
<tr>
<td>gastric DLBCL</td>
</tr>
</tbody>
</table>
Figure 3

A

B

C

D

E

F

G

- Aza

Aza + PBA

- Aza

Aza + PBA

ABL1

α-TUB

ABL1 expression

Normalized expression

- N/C

pre-miR-203

- 50 100

50 100

(μM)

- N/C

pre-miR-203

- 50 100

50 100

(μM)

H3-Threonine (cpm)
Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis

Vanessa J Craig, Sergio B Cogliatti, Hubert Rehrauer, et al.

Cancer Res Published OnlineFirst March 31, 2011.

Updated version Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-10-3907

Supplementary Material Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2011/03/31/0008-5472.CAN-10-3907.DC1

Author Manuscript Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/early/2011/03/30/0008-5472.CAN-10-3907. Click on “Request Permissions” which will take you to the Copyright Clearance Center’s (CCC) Rightslink site.